Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

207 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations.
Dowling RJO, Kalinsky K, Hayes DF, Bidard FC, Cescon DW, Chandarlapaty S, Deasy JO, Dowsett M, Gray RJ, Henry NL, Meric-Bernstam F, Perlmutter J, Sledge GW, Bratman SV, Carey LA, Chang MC, DeMichele A, Ennis M, Jerzak KJ, Korde LA, Lohmann AE, Mamounas EP, Parulekar WR, Regan MM, Schramek D, Stambolic V, Thorat MA, Whelan TJ, Wolff AC, Woodgett JR, Sparano JA, Goodwin PJ. Dowling RJO, et al. Among authors: mamounas ep. JNCI Cancer Spectr. 2019 Aug 10;3(4):pkz050. doi: 10.1093/jncics/pkz050. eCollection 2019 Dec. JNCI Cancer Spectr. 2019. PMID: 32337479 Free PMC article.
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.
Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR. Winer EP, et al. Among authors: mamounas ep. J Clin Oncol. 2005 Jan 20;23(3):619-29. doi: 10.1200/JCO.2005.09.121. Epub 2004 Nov 15. J Clin Oncol. 2005. PMID: 15545664 Review.
NCCN Task Force Report: Adjuvant Therapy for Breast Cancer.
Carlson RW, Brown E, Burstein HJ, Gradishar WJ, Hudis CA, Loprinzi C, Mamounas EP, Perez EA, Pritchard K, Ravdin P, Recht A, Somlo G, Theriault RL, Winer EP, Wolff AC; National Comprehensive Cancer Network. Carlson RW, et al. Among authors: mamounas ep. J Natl Compr Canc Netw. 2006 Mar;4 Suppl 1:S1-26. J Natl Compr Canc Netw. 2006. PMID: 16507275 Review.
Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference.
Buchholz TA, Lehman CD, Harris JR, Pockaj BA, Khouri N, Hylton NF, Miller MJ, Whelan T, Pierce LJ, Esserman LJ, Newman LA, Smith BL, Bear HD, Mamounas EP. Buchholz TA, et al. Among authors: mamounas ep. J Clin Oncol. 2008 Feb 10;26(5):791-7. doi: 10.1200/JCO.2007.15.0326. J Clin Oncol. 2008. PMID: 18258988 Review.
Recommendations for research priorities in breast cancer by the coalition of cancer cooperative groups scientific leadership council: imaging and local therapy.
Sparano JA, Pisano ED, White JR, Hunt KK, Mamounas EP, Perez EA, Hortobagyi GN, Gralow JR, Comis RL. Sparano JA, et al. Among authors: mamounas ep. Breast Cancer Res Treat. 2010 Apr;120(2):273-84. doi: 10.1007/s10549-009-0655-z. Epub 2009 Dec 19. Breast Cancer Res Treat. 2010. PMID: 20024613 Review.
Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors.
Tang G, Cuzick J, Costantino JP, Dowsett M, Forbes JF, Crager M, Mamounas EP, Shak S, Wolmark N. Tang G, et al. Among authors: mamounas ep. J Clin Oncol. 2011 Nov 20;29(33):4365-72. doi: 10.1200/JCO.2011.35.3714. Epub 2011 Oct 17. J Clin Oncol. 2011. PMID: 22010013 Free PMC article.
Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG); Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J, Gray R, Pierce L, Whelan T, Wang Y, Peto R. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), et al. Lancet. 2011 Nov 12;378(9804):1707-16. doi: 10.1016/S0140-6736(11)61629-2. Epub 2011 Oct 19. Lancet. 2011. PMID: 22019144 Free PMC article. Review.
Drug development: neoadjuvant opportunities in breast cancer.
Rastogi P, Geyer CE, Mamounas EP, DeMichele A. Rastogi P, et al. Among authors: mamounas ep. Am Soc Clin Oncol Educ Book. 2013:73-9. doi: 10.14694/EdBook_AM.2013.33.73. Am Soc Clin Oncol Educ Book. 2013. PMID: 23714461 Free article.
Past, present, and future challenges in breast cancer treatment.
Sledge GW, Mamounas EP, Hortobagyi GN, Burstein HJ, Goodwin PJ, Wolff AC. Sledge GW, et al. Among authors: mamounas ep. J Clin Oncol. 2014 Jul 1;32(19):1979-86. doi: 10.1200/JCO.2014.55.4139. Epub 2014 Jun 2. J Clin Oncol. 2014. PMID: 24888802 Free PMC article. No abstract available.
207 results